Floatz logo

Pvgi.1

Critical Limb Ischemia

gene_therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Critical Limb Ischemia cohort.

Asset / SponsorPhaseRating
Peripheral Blood Mononuclear Cell
Mahidol University
Phase 3BB
Pregabalin
Karolinska Institutet
Phase 4BB
TREPROSTINIL PHOSPHATE
United Therapeutics
Phase 3B
PCK-HGFX7
Helixmith Co., Ltd.
Phase 2B
TREPROSTINIL DIETHANOLAMINE
Southern Arizona Vascular Institute
Phase 2CCC
Endothelial Progenitor Cells
Allife Medical Science and Technology Co., Ltd.
Phase 1CC

Same molecule, other indications

Pvgi.1 is also rated in:

ulcer of lower limbsDormant
CC
Indicative ·
47 / 100
View asset →
ischemic diseaseDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →